Navigation Links
Thinsite

ProductsThinsite
Company Art Optical Contact Lens, Inc.
Item Thinsite
Features Junctionless aspheric front and back surfaces reduce lid interaction and lens awareness for easier, faster adaptation. Increased EOP leads to better corneal health. Reduced lens mass provides increased oxygen performance compared to standard-thickness designs. The reduced lens mass also allows for greater centering of the optical zone. Stability and flexural resistance of standard center thickness designs for ultimate durability. A consistently thinner overall lens profile in all minus powers reduces lens awareness.
Description Thinsite is designed using sophisticated lathing techniques, intrinsically permeable polymers and advanced mathematical concepts. Thinsite lenses feature a center thickness of just 0.08 across all minus power ranges. While all plus powered Thinsite lenses maintain a 30% decrease in center thickness over standard designs. The unique design eliminates stress points to reduce the chance of lens warpage or flexure.
Info Art Optical Contact Lens, Inc.
Customer Service: 800.253.9364
Web site: http://www.artoptical.com/

Related medicine products :

1. Boston Multivision
2. Boston Simplus Multi-Action solution
3. Boston Post-Op Hip Orthosis
4. Boston Scoliosis Brace
5. Soft Boston Scoliosis Brace™
6. Boston Keratoprosthesis
TAG: Thinsite
...: The HF-compatible V series from Pentax, the stan...asured., ,The HF-compatible series of fibre bronc...V and FB-15V models along with the very slim FB-10... quality thanks mainly to the higher resolution an...
...m the latest 60 series bronchoscopes., ,Olymp... providing clinicians with superior specifications...ressive range of fiberoptic instruments for diagno...he demands of increasing peripheral bronchoscopy.,...
The BRO-YP2 is Fujinon's pediatric fiberoptic bronchoscope. Its small outside diameter allows for more comfortable transnasal insertion. The standard 2.0mm channel provides sufficient suction and acc
...m the latest 60 series bronchoscopes., ,Olymp... providing clinicians with superior specifications...ressive range of fiberoptic instruments for diagno...he demands of increasing peripheral bronchoscopy.,...
Medicine Products:
(Date:5/16/2008)...rstCall/ -- Tempo Participacoes,S.A. (Bovespa: TEM...ding,provider of healthcare administration service... services, announces today its results for the fir...formation contained herein,except where otherwise...,accordance with Brazilian Stock Exchange Commissi...
(Date:5/15/2008)...sing in Targeting Cancer Cells, ...ay 15 /PRNewswire-FirstCall/ -- Abbott scientists,...everal investigative,compounds in the company,s on... Clinical Oncology (ASCO) Annual Meeting, schedule... ABT-263, a Bcl-2 family protein,antagonist, and A...
(Date:5/15/2008)...ng cancer treatment for each individual, researche...resented a study suggesting a simple blood test ca...cacy for patients with metastatic breast cancer. ,...to determine if a particular cancer treatment is w...y significant radiographic changes in tumor size o...
(Date:5/15/2008)...tCall/ -- Digital Power,Corporation (Amex: DPW ) ...cial results for the first quarter ended March 31,...000 for the quarter ended,March 31, 2008, an incre...last year. An operating loss of $165,000 for the f...operating profit of $25,000 for the same quarter,l...
Breaking Medicine News(10 mins):Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 2Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 3Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 4Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 5Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 6Health News:Study suggests blood test can help improve treatment outcomes for breast cancer patients 2Health News:Digital Power Reports Financial Results for the First Quarter Ended March 31, 2008 2Health News:Digital Power Reports Financial Results for the First Quarter Ended March 31, 2008 3
... of the primary diseases affecting the children be...easons. RSV infections start by the end of Novembe...y the month of December. // Deborah Lehman, MD, as... diseases and HIV at Cedars-Sinai Medical Center s...
...Bower, Ph.D. of the University of California at Lo...ry much prevalent among breast cancer survivors. /...ndergone breast cancer surgery and asked them to f...d shocking results that one third of the women suf...
...UK could be hit by a shortage of doctors. Public ... reforms mean stalling of their careers and withdr...unding primary care trust mergers in England under...S has prompted some primary care trusts to freeze ...
...e been aborted in India in the last couple of deca...y The Lancet. // Fewer girls than boys are born in...Hospital, University of Toronto, Canada), Rajesh K... Education and Research, Chandigarh, India) and co...
Other Medicine News:Health News:Parental Knowledge Of RSV Infections Is Vital 2Health News:10 Million Indian Females Aborted In 20 years 2
(Date:5/16/2008)...r Novel Approach to Blood ...wire-FirstCall/ -- Pharmacopeia (Nasdaq:,PCOP), an...el small,molecule therapeutics, announced today th...or Antagonist (DARA), showed statistically signifi... in patients with mild to,moderate hypertension. P...
(Date:5/15/2008)...- Eisai Corporation of North,America announced tod...out,compounds in the company,s oncology pipeline, ...h have been accepted for presentation at the,44th ... Oncology (ASCO),taking place in Chicago from May... on Eisai marketed products and,investigational co...
(Date:5/15/2008)...ety profile of BSI-201 in subjects...May 15 /- BiPar Sciences, Inc., a,pri...ovel cancer therapies,today announced that data s...e presented at the 2008 American Society of Clinic...will be presented from the first in human Phase 1 ...
(Date:5/15/2008)...rstCall/ -- Cytopia Limited,(ASX: CYT) today annou...ntation on CYT997 at the 2008 Annual Meeting of th...l be accessible to the public via ASCO,s,website ... (US EDT)., The oral presentation, entitled "Phas...scular disrupting agent, in patients with advanced...
Breaking Medicine Technology:Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Tata Consultancy Services to Support Roches Global Capacity Building Initiative 455 1Tata Consultancy Services to Support Roches Global Capacity Building Initiative 455 2Tata Consultancy Services to Support Roches Global Capacity Building Initiative 455 3Mega Events in September Allow Heart Health Campaign to Reach Tens of Thousands of Hispanics During Cholesterol Awareness Month 450 1Mega Events in September Allow Heart Health Campaign to Reach Tens of Thousands of Hispanics During Cholesterol Awareness Month 450 2Mega Events in September Allow Heart Health Campaign to Reach Tens of Thousands of Hispanics During Cholesterol Awareness Month 450 3Mega Events in September Allow Heart Health Campaign to Reach Tens of Thousands of Hispanics During Cholesterol Awareness Month 450 4Mega Events in September Allow Heart Health Campaign to Reach Tens of Thousands of Hispanics During Cholesterol Awareness Month 450 5Mega Events in September Allow Heart Health Campaign to Reach Tens of Thousands of Hispanics During Cholesterol Awareness Month 450 6Nanotechnology 3A Whats that 3F 244 1Nanotechnology 3A Whats that 3F 244 2Avocados may help prevent oral cancer OSU study shows 443 1Avocados may help prevent oral cancer OSU study shows 443 2
... in Evaluating Drug,Efficacy; Dr. H. Bryan Brewer,...EASANTON, CA, Mar 30, 2007 (MARKET WIRE via COMTEX...PD) Dr. H. Bryan Brewer, Jr.,Chief Scientific Dir...wide range of presentations at the recent American...s that the rationale for HDL,being the next, most ...
...al and Social,Performance, COLORADO SPRINGS, C... treatment with INVEGA(TM) (paliperidone),Extend...on for,schizophrenia, helped many patients effec... improvements in personal and social,functioning...el, international,clinical trial sponsored by Ja...
Other Medicine Technology:Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 2Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 3Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 4Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 5Study Suggests Invega Helps Patients With Schizophrenia Maintain,Symptom Control 2Study Suggests Invega Helps Patients With Schizophrenia Maintain,Symptom Control 3Study Suggests Invega Helps Patients With Schizophrenia Maintain,Symptom Control 4Study Suggests Invega Helps Patients With Schizophrenia Maintain,Symptom Control 5Study Suggests Invega Helps Patients With Schizophrenia Maintain,Symptom Control 6